Physician profile
Rhonda Lee Hill
NPI 1215336474
$19,873.91
in general payments reported to CMS, 2019-2025
64 companies · $3,976 in 2025
The $3,976 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,231 · 2022: $4,895 · 2023: $4,684 · 2024: $4,088 · 2025: $3,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,538.33 |
| Education | $209.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,379.35 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $2,819.06 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,318.62 | 2021-2025 | Ofev, Stiolto Respimat, Jardiance |
| Amgen INC. | $1,282.77 | 2021-2025 | Otezla, Repatha, Tezspire |
| Regeneron Healthcare Solutions, INC. | $999.32 | 2022-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $865.15 | 2021-2025 | |
| Genzyme Corporation | $792.99 | 2022-2025 | |
| Genentech USA, INC. | $657.02 | 2022-2025 | Xolair |
| Mylan Specialty L.P. | $634.57 | 2021-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $614.81 | 2021-2025 | Glassia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $454.50 | 2021-2025 | Xifaxan |
| Astellas Pharma US INC | $400.97 | 2022-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $360.88 | 2021-2025 | |
| Abbvie INC. | $331.44 | 2021-2025 | |
| Lilly USA, LLC | $327.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $324.44 | 2021-2022 | |
| Grifols USA, LLC | $319.09 | 2021-2025 | Prolastin-C Liquid |
| Novo Nordisk INC | $317.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $243.37 | 2022-2025 | Rexulti, Abilify Maintena |
| Insmed, INC. | $241.11 | 2022-2025 | Arikayce, Brinsupri |
| Pfizer INC. | $239.60 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $209.56 | 2023-2025 | Gemtesa |
| Daiichi Sankyo INC. | $204.71 | 2021-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $192.27 | 2022-2024 | |
| Inspire Medical Systems, INC. | $189.30 | 2023-2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $176.60 | 2024-2025 | Voquezna |
| Baxter Healthcare | $158.97 | 2022-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $139.37 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $134.22 | 2021-2025 | Tyvaso, Tyvaso |
| Boston Scientific Corporation | $125.76 | 2022-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $112.89 | 2021-2024 | Verquvo, Belsomra |
| Mallinckrodt Hospital Products INC. | $109.95 | 2022-2025 | Acthar |
| Corium, LLC | $97.91 | 2023 | Adlarity |
| Electromed, INC. | $96.36 | 2024-2025 | Smartvest |
| Biohaven Pharmaceutical Holding Company LTD. | $81.49 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $79.17 | 2023-2025 | Uptravi, Opsumit |
| Nestle Healthcare Nutrition INC. | $74.69 | 2021-2022 | |
| Viatris Specialty LLC | $67.38 | 2025 | Yupelri |
| Harmony Biosciences LLC | $58.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $52.31 | 2022-2023 | Quviviq |
| Resmed Corp | $48.67 | 2025 | |
| Avanir Pharmaceuticals, INC. | $40.76 | 2021-2022 | |
| Averitas Pharma INC. | $39.42 | 2023-2024 | Qutenza |
| Vifor Pharma, INC. | $38.37 | 2024 | Veltassa, Zemaira |
| Amarin Pharma, INC. | $38.07 | 2021 | |
| Medtronic, INC. | $36.94 | 2023-2024 | Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $35.10 | 2021-2022 | |
| Inogen, INC. | $31.69 | 2022-2023 | Inogen At Home Stationary Concentrator |
| Exact Sciences Corporation | $28.60 | 2023-2024 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $24.80 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ardelyx, INC. | $19.94 | 2024 | Ibsrela |
| Irhythm Technologies, INC. | $19.24 | 2024 | Zio Xt Patch, Zio Monitor |
| 3b Medical, INC. | $18.84 | 2025 | Luna |
| Abbott Laboratories | $18.77 | 2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $18.71 | 2022 | |
| Gilead Sciences, INC. | $17.51 | 2024 | |
| Dexcom, INC. | $16.10 | 2024 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $15.85 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.67 | 2024 | Caplyta |
| Lundbeck LLC | $13.93 | 2023 | Rexulti |
| Fisher & Paykel Healthcare INC | $13.62 | 2022 | |
| Pulmonx Corporation | $13.61 | 2021 | |
| Nabriva Therapeutics, Plc | $12.76 | 2022 | |
| Collegium Pharmaceutical, INC. | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.